PT  - JOURNAL ARTICLE
AU  - Roland Seifert
TI  - Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?
AID  - 10.1124/jpet.116.234245
DP  - 2016 Aug 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 242--243
VI  - 358
IP  - 2
4099  - http://jpet.aspetjournals.org/content/358/2/242.short
4100  - http://jpet.aspetjournals.org/content/358/2/242.full
SO  - J Pharmacol Exp Ther2016 Aug 01; 358
AB  - There is an ongoing discussion about the value of adenylyl cyclase 5 (AC5) as drug target for treatment of heart failure. This letter discusses statistical, pharmacokinetic, and pharmacodynamic reasons why the recently proposed cardioprotective effects of vidarabine cannot be readily attributed to AC5 inhibition.